<DOC>
	<DOCNO>NCT01422876</DOCNO>
	<brief_summary>This trial evaluate use BI 10773/linagliptin daily ( qd ) fix dose combination ( FDC ) treatment naïve metformin treat patient type 2 diabetes mellitus support approval regulatory authority .</brief_summary>
	<brief_title>Efficacy Safety Empagliflozin ( BI 10773 ) / Linagliptin ( BI 1356 ) Fixed Dose Combination Treatment naïve Metformin Treated Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus prior inform consent 2 . Male female patient diet exercise regimen drugnaïve ( define absence oral antidiabetic therapy , glucagon like peptide1 analog insulin 12 week prior randomization ) pretreated metformin ( =1500 mg/day maximum tolerate dose maximum dose accord local label ) unchanged 12 week prior randomisation . 3 . Glycosylated hemoglobin ( HbA1c ) = 7.0 % = 10.5 % ( = 53.0 mmol/mol = 91.3 mmol/mol ) Visit 1 ( screen ) Exclusion criterion : 1 . Uncontrolled hyperglycemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) . 2 . Any antidiabetic drug within 12 week prior randomization ( except metformin background therapy define via inclusion criterion 2 ) 3 . Acute coronary syndrome ( nonST elevation myocardial infarction , ST elevation myocardial infarction unstable angina pectoris ) , stroke ( transient ischemic attack ) TIA within 3 month prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>